What’s next for PARP inhibitors in early breast cancer? Drs. Iyengar and Robson look ahead to how MRD testing, novel ADCs, and genomic evolution may reshape adjuvant therapy for BRCA-mutated disease in the years to come.
The Future of Adjuvant PARP Therapy: MRD, ADCs, and Beyond
You may also like
Recommended Videos
